Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 16/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609814 | 0.84 | NAMPT (0.52) | GSK3BDYRK1ANAMPT | |
| SCHEMBL1126145 | 0.84 | RAB9A (0.62) | GSK3BDYRK1A | |
| SCHEMBL17577318 | 0.83 | DEGS1 (0.60) | DEGS1 | |
| SCHEMBL4398253 | 0.83 | GSK3B (0.44) | DEGS1GSK3BDYRK1ANAMPTGRIN2B | |
| SCHEMBL283737 | 0.83 | RAB9A (0.51) | — | |
| SCHEMBL29372377 | 0.83 | RAB9A (0.51) | — | |
| SCHEMBL56219 | 0.83 | PTGS1 (0.50) | GSK3BDYRK1ANAMPTGRIN2B | |
| SCHEMBL12461458 | 0.83 | GSK3B (0.44) | DEGS1GSK3BDYRK1ANAMPTGRIN2B | |
| SCHEMBL2307440 | 0.83 | GSK3B (0.44) | DEGS1GSK3BDYRK1ANAMPTGRIN2B | |
| SCHEMBL30231113 | 0.83 | GSK3B (0.44) | DEGS1GSK3BDYRK1ANAMPTGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177382-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| WO-2023028077-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2022226182-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2432771-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | DEGS1 857/4885GSK3B 2014/4885DYRK1A 3331/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | DEGS1 876/4885GSK3B 2340/4885DYRK1A 3182/4885 |
| US-20250177382-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | DEGS1 4588/4885GSK3B 477/4885DYRK1A 1470/4885 |
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | DEGS1 3682/4885GSK3B 1535/4885DYRK1A 4011/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | DEGS1 3682/4885GSK3B 1535/4885DYRK1A 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.